Scholarlink

Background <p><i>Acinetobacter baumannii</i> is the primary cause of persistent opportunistic infections in healthcare settings, recognized as a global priority due to its resistance to antibiotic therapy. Quorum sensing and biofilm formation are the key factors driving the pathogenesis and drug resistance of <i>A. baumannii</i>. Nanostructures demonstrated encouraging promise in enhancing the therapeutic efficacy and overcoming treatment failure. Therefore, the efficacy of staphyloxanthin (STX)-encapsulated niosomes was evaluated both in vitro and in vivo.</p> Results <p>The formulated niosomal nanovesicles displayed a spherical shape at the nanoscale (177.8&#xa0;nm), featuring a slow-release rate (39.6%) and appropriate entrapment efficiency (92.7%). Our results demonstrated that STX exhibited strong antibacterial activity, with MIC values up to 16&#xa0;µg/mL against multidrug-resistant isolates (<i>n</i> = 24). The in vitro findings revealed that the encapsulation of STX within niosomal nanovesicles demonstrated superior therapeutic efficacy compared to the free solution. This improvement was reflected by a significant reduction in biofilm formation (68–88%), motility (66.66–94.45%), and siderophore production (48.75–79.5%), as well as marked disruption of the mature biofilm by 82%. The anti-quorum sensing activity of STX was further confirmed the attenuation of biofilm and virulence, as evidenced by downregulation of <i>abaI</i> expression (1.42-fold reduction) and molecular docking simulations. It is noteworthy that the biological findings revealed a significant eradication of meropenem-induced persister cells after the addition of niosomal dispersion. The preclinical investigations prove the efficacy of STX in improving survival rates through reducing the bacterial burden (2-fold reduction) and lethal inflammatory consequences in a mouse model of pneumonia.</p> Conclusion <p>our results suggested that STX may serve as a promising alternative for combating <i>A. baumannii</i> biofilms and persister cells.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Deciphering the efficacy of staphyloxanthin-encapsulated niosomal nanovesicles to attenuate biofilm formation, quorum sensing, and meropenem persistence in Acinetobacter baumannii

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月13日

查看全文
  • Ahmed M. Nosair,
  • Ahmed A. Abdelaziz,
  • Amal M. Abo-Kamar,
  • Lamiaa A. Al-Madboly,
  • Mahmoud H. Farghali

摘要

Background

Acinetobacter baumannii is the primary cause of persistent opportunistic infections in healthcare settings, recognized as a global priority due to its resistance to antibiotic therapy. Quorum sensing and biofilm formation are the key factors driving the pathogenesis and drug resistance of A. baumannii. Nanostructures demonstrated encouraging promise in enhancing the therapeutic efficacy and overcoming treatment failure. Therefore, the efficacy of staphyloxanthin (STX)-encapsulated niosomes was evaluated both in vitro and in vivo.

Results

The formulated niosomal nanovesicles displayed a spherical shape at the nanoscale (177.8 nm), featuring a slow-release rate (39.6%) and appropriate entrapment efficiency (92.7%). Our results demonstrated that STX exhibited strong antibacterial activity, with MIC values up to 16 µg/mL against multidrug-resistant isolates (n = 24). The in vitro findings revealed that the encapsulation of STX within niosomal nanovesicles demonstrated superior therapeutic efficacy compared to the free solution. This improvement was reflected by a significant reduction in biofilm formation (68–88%), motility (66.66–94.45%), and siderophore production (48.75–79.5%), as well as marked disruption of the mature biofilm by 82%. The anti-quorum sensing activity of STX was further confirmed the attenuation of biofilm and virulence, as evidenced by downregulation of abaI expression (1.42-fold reduction) and molecular docking simulations. It is noteworthy that the biological findings revealed a significant eradication of meropenem-induced persister cells after the addition of niosomal dispersion. The preclinical investigations prove the efficacy of STX in improving survival rates through reducing the bacterial burden (2-fold reduction) and lethal inflammatory consequences in a mouse model of pneumonia.

Conclusion

our results suggested that STX may serve as a promising alternative for combating A. baumannii biofilms and persister cells.